



1614

January 5, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of M. Seveso, D. O'Mahony and D. Page

Application No. 09/743,173

Examiner: Not Yet Assigned

Filed January 14, 2002

Group Art Unit 1614

ENHANCED DELIVERY OF NUCLEIC ACID BASED DRUGS

(Attorney Docket No. P24,376-A USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence, along with any other papers indicated as being enclosed, is being deposited with the United States Postal Services, as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on January 5, 2004.


Todd Conway

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(B)

Sir:

It is requested respectfully that the information identified on the enclosed Form PTO-1449 (Modified) be made of record and considered with respect to the above-referenced patent application. A copy of each item of information identified on the

Applicants: M. Seveso, D. O'Mahony
and D. Page
Application No.: 09/743,173

Form is enclosed. The Examiner is requested to indicate that each item on the enclosed Form PTO-1449 (Modified) has been considered by initialing and dating the enclosed Form and returning a copy of same to the undersigned.

This Information Disclosure Statement is believed to be filed before a first Office Action on the merits. Identification of information on the attached Form, or in this statement, is not an admission that such information is prior art to the invention claimed in the present application or that such information is in an analogous art area.

The present application is a U.S. National Stage application under 35 U.S.C. §371 based on and claiming the priority of International Application No. PCT/GB00/01726 which designates the U.S. and which was filed May 5, 2000, which application in turn is based on and claims the priority of U.S. Provisional Application no. 60/132,603, filed May 5, 1999. These application are relied upon for their earlier filing dates under 35 U.S.C. §§363 and 120 respectively.


Publications BA through BH were cited in the present application on pages 1 and 2. Applicants note that publication BH was incorrectly cited in the application on page 2, line 5 as "1995, J. Pharmacol. Toxicol. 275, 462" this error is corrected on the enclosed form 1449 modified.

Publications AN through AR were cited in the International Preliminary Examination Report (dated November 15, 2000) of the aforementioned International Application. Publication AR was also cited in the present application on page 2 at line 30.

Applicants: M. Seveso, D. O'Mahony
and D. Page
Application No.: 09/743,173

The Commissioner is authorized hereby to charge any fees or credit any overpayment associated with this Statement (copy enclosed) to Deposit Account Number 19-5425.

Respectfully submitted,



H. Eric Fischer
Registration No. 46,010

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Telephone (215) 923-4466
Facsimile (215) 923-2189

M:\CMcAvoy\IDS Program\Elan\P24376A USA\P24376 A USA - Letter re Form 1449 (Modified).wpd

FORM PTO-1449 (MODIFIED)

JAN 07 2004

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT
(USE SEVERAL SHEETS IF NECESSARY)**

U.S. Department of Commerce
Patent and Trademark Office

ATTORNEY DOCKET NO. P24,376-A USA APPLICATION NO. 09/743,173

APPLICANT M. Seves , D. O'Mahony, D. Page

FILING DATE January 14, 2002 GROUP ART UNIT 1614

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	DATE	COUNTRY
	AN	0 890 362 A	01/13/1999	EP
	AO	95 26718 A	10/12/1995	WO
	AP	00 02601 A	01/20/2000	WO
	AQ	99 60167 A	11/25/1999	WO
	AR	99 01579 A	01/14/1999	WO

OTHER PUBLICATIONS

BA	Akhtar, "Antisense Technology: Selection and Delivery of Optimally Acting Antisense Oligonucleotides," J. Drug Targeting, 5(4):225-234 (1998)
BB	Bennett et al., "DNA Binding to Human Leukocytes," J. Clin. Invest., 76:2182-2190 (1985)
BC	Chin et al., "Rapid Nuclear Accumulation of Injected Oligodeoxyribonucleotides," New Biol. 9:1091-1100 (1990)
BD	Loke et al., "Characterization of Oligonucleotide Transport into Living Cells," Proc. Natl. Acad. Sci. U.S.A., 86:3474-3478 (1989)
BE	Stein et al., "Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: characterization and preliminary kinetics of cellular uptake," Gene, 72:333-341(1988)
BF	Stein, "Phosphorothioate Antisense Oligodeoxyribonucleotides: Questions of Specificity," Trends Biotechnology, 14(5):147-49 (1996)
BG	Yakubov et al., "Mechanism of Oligonucleotide Uptake by Cells: Involvement of Specific Receptors," Proc. Natl. Acad. Sci. U.S.A., 86:6454-6458 (1989)
BH	Crooke et al., " <i>In Vitro</i> Pharmacokinetics of Phosphorothioate Antisense Oligonucleotides," J. Pharmacology and Exp. Therapeutics., 275(1):462-473 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation *and* not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

January 5, 2004